The Boys Who Beat the FDA
Miracles happen. The Food and Drug Administration on Monday approved a drug for muscular dystrophy after months of delay and bureaucratic infighting. This is a triumph for scientific innovation, and for
young men who will live better and more independently—if the bureaucracy doesn’t strike back.
FDA announced accelerated approval for eteplirsen by Sarepta Therapeutics more than 100 days after the agency’s legally mandated decision date. The therapy is the first for Duchenne muscular dystrophy patients, typically boys who...